Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Net Income towards Common Stockholders of -$7.7 million for Q1 2026, down 98.81% year-over-year from -$645.3 million in Q1 2025, and down 10.47% quarter-over-quarter from -$7.0 million in Q4 2025.
Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$7.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 98.81% year-over-year to -$7.7 million; the TTM figure through Mar 2026 stood at -$25.0 million (down 121.77% YoY), while the FY2025 annual figure was -$21.2 million, down 89.66% from the prior year.
- Net Income towards Common Stockholders fell to -$7.7 million in Q1 2026 per VVOS's latest filing, from -$7.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.4 million in Q4 2023 and bottomed at -$7.7 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$3.8 million across 5 years, with a median of -$5.0 million in 2025.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 253.83% — and 2025, when it slumped 159.74%.
- Vivos Therapeutics' Net Income towards Common Stockholders stood at -$6.1 million in 2022, then soared by 253.83% to $9.4 million in 2023, then plunged by 130.8% to -$2.9 million in 2024, then slumped by 141.04% to -$7.0 million in 2025, then declined by 10.47% to -$7.7 million in 2026.
- Business Quant data shows VVOS's Net Income towards Common Stockholders at -$7.7 million in Q1 2026, -$7.0 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Vivos Therapeutics | 4.95 Mn | 3.15 Mn | 2.95 Mn | -5.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.68 Mn |
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -3.86 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -2.62 Mn |
| Jun 30, 2024 | -1.93 Mn |
| Mar 31, 2024 | -3.76 Mn |
| Dec 31, 2023 | 9.37 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -5.53 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -6.09 Mn |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -5.33 Mn |
| Dec 31, 2021 | -7.39 Mn |
| Sep 30, 2021 | -5.45 Mn |
| Jun 30, 2021 | -4.04 Mn |